Sierra Oncology Inc (SRRA) Stock Gains 100.00% This Week: How Does it Score?

Monday, December 2, 2019 2:45 PM | InvestorsObserver Analysts

Sierra Oncology Inc (SRRA) stock is down -68.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives SRRA stock a score of 42 out of a possible 100.

That score is chiefly influenced by a short-term technical score of 21. SRRA's score also includes a long-term technical score of 21. The fundamental score for SRRA is 85. In addition to the average rating from Wall Street analysts, SRRA stock has a mean target price of 3. This means analysts expect the stock to climb 500.00% over the next 12 months.

Click Here to get the full Stock Score Report on Sierra Oncology Inc (SRRA) Stock.

What's Happening with SRRA Stock Today

Sierra Oncology Inc (SRRA) stock is up 44.19% while the S&P 500 is down -0.58% as of 2:43 PM on Monday, Dec 2. SRRA is higher by $0.15 from the previous closing price of $0.35 on volume of 14,923,461 shares. Over the past year the S&P 500 is higher by 11.91% while SRRA is down -68.35%. SRRA lost -$0.74 per share in the over the last 12 months.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

40% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 57% with annual

InvestorsObserver Premium

$ 20.75 $ 12.45 /month
$249 $149.40 billed annually

You May Also Like

Related Articles

Sector Update: Biotechs Drag Health Care Stocks Lower

Stocks Poised to Close Higher Friday on COVID-19 Treatment Optimism

Sector Update: Health Care

Is Price of INO Stock Justified by its Earnings?

Related Companies